PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9126230

Prostate-specific antigen density.

M C Beduschi·J E Oesterling
View original source ↗Export metadata ↓

Abstract

Nearly 20 years have passed since PSA was definitively identified. Throughout this period, its clinical application as a tumor marker has expanded significantly. Today, besides monitoring prostate cancer therapy, PSA is being used extensively in mass screening programs for early detection of adenocarcinoma of the prostate and has become the most important tumor marker in urologic oncology. Although of unquestionable importance, PSA is not the perfect marker because of its lack of efficacy in discriminating BPH from prostate cancer. In order to enhance its sensibility, specificity, and predictive value, a series of variables influencing PSA levels have been studied and new parameters developed to correct discrepancies or confounding factors. Recognition of the relationship between PSA, prostate volume, and their interference with serum PSA levels made possible the development of the PSAD concept. Its wide application in different sets of patients for diagnostic and staging purposes resulted in enough data to demonstrate its usefulness and cost effectiveness as a second-line screening parameter, helping to distinguish BPH from prostate cancer in patients with PSA levels in the intermediate area, and avoiding some unnecessary biopsies. Even though PSAD does not offer a definitive solution for prostate cancer screening or management, its association with all the other diagnostic methods may offer the best way to assess the population at risk and assure their well-being (Fig. 5).

Explore related subjects

HumansMaleProstateProstate-Specific AntigenProstatic NeoplasmsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M C Beduschi, J E Oesterling. 1997. Prostate-specific antigen density.. https://doi.org/10.1016/s0094-0143(05)70379-7

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2027

Global Genomic Surveillance.

Global genomic surveillance has emerged as a foundational pillar of public health in the twenty-first century, enabling real-time tracking of pathogen evolution and informing outbreak response. This chapter examines the strategic architecture of global genomic surveillance, focusing on its application to arboviruses such as chikungunya virus (CHIKV). It explores the integration of genomic data with epidemiological, clinical, and environmental information within a One Health framework, while addressing critical challenges in governance, equity, and interoperability. The discussion covers the entire genomic surveillance workflow, from sample collection and sequencing to bioinformatic analysis and phylogenetic inference, and highlights the transformative role of artificial intelligence (AI) in predictive surveillance. By analyzing global initiatives, operational barriers, and emerging technologies, this chapter underscores the necessity of sustainable, equitable, and interoperable genomic systems to proactively address current and future infectious disease threats.

Humans↗
PubMed2027

Systematic Dissection of Key Driver Perturbation Signatures in Single Cells via ECCITE-seq.

CRISPR screens, such as expanded CRISPR-compatible cellular indexing of transcriptomes and epitopes by sequencing (ECCITE-seq), enable the simultaneous measurement of transcriptomes, gRNA identity, and cell-surface protein expression at single-cell resolution to systematically interrogate gene function. This platform provides a powerful and scalable experimental approach for validating disease-associated regulators identified by large-scale association studies and other computational methods, including network-based analyses of multi-omics data. Here, as an example application, we describe an ECCITE-seq framework to characterize the transcriptomic consequences of perturbing multiple neuronal key driver genes associated with Alzheimer's disease (AD) in human-induced pluripotent stem cell (hiPSC)-derived neurons. More broadly, by integrating customized pooled gRNA libraries with different CRISPR effectors across multiple cell types, this approach allows for the assessment of the regulatory impact of candidate genes implicated in development and disease processes.

Humans↗
PubMed2027

Identification of Genome-Wide Chromatin Structural Aberration in Cancer by Hi-C Analysis.

Aberrant three-dimensional genome organization is a hallmark of cancer, often driving oncogene activation through mechanisms such as enhancer hijacking. High-throughput chromosome conformation capture (Hi-C) maps these interactions on a genome-wide scale. Unlike earlier dilution-based methods, in situ Hi-C performs proximity ligation within intact nuclei, minimizing random ligation noise and enabling fine-scale structure detection. This chapter describes an optimized in situ Hi-C protocol tailored for cancer cell lines using MboI digestion and biotin-mediated pull-down to generate high-complexity libraries. We further outline a computational workflow that extends beyond standard topological mapping of compartments and topologically associating domains to identify cancer-specific aberrations. Specifically, we focus on detecting chromosomal rearrangements (structural variants) and characterizing the distinct circular topology of extrachromosomal DNA. This integrated experimental and analytical framework provides the necessary tools to dissect the spatial dysregulation underlying tumor evolution.

Humans↗